RU2006118312A - Бензимидазолы, полезные в качестве модуляторов ионных каналов - Google Patents
Бензимидазолы, полезные в качестве модуляторов ионных каналов Download PDFInfo
- Publication number
- RU2006118312A RU2006118312A RU2006118312/04A RU2006118312A RU2006118312A RU 2006118312 A RU2006118312 A RU 2006118312A RU 2006118312/04 A RU2006118312/04 A RU 2006118312/04A RU 2006118312 A RU2006118312 A RU 2006118312A RU 2006118312 A RU2006118312 A RU 2006118312A
- Authority
- RU
- Russia
- Prior art keywords
- pain
- independently selected
- formula
- nitrogen
- oxygen
- Prior art date
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 56
- 229910052757 nitrogen Inorganic materials 0.000 claims 49
- 229910052717 sulfur Inorganic materials 0.000 claims 40
- 229910052760 oxygen Inorganic materials 0.000 claims 38
- 125000001931 aliphatic group Chemical group 0.000 claims 35
- 208000002193 Pain Diseases 0.000 claims 32
- 125000005842 heteroatom Chemical group 0.000 claims 31
- 230000036407 pain Effects 0.000 claims 30
- 239000001301 oxygen Chemical group 0.000 claims 29
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 27
- 125000004434 sulfur atom Chemical group 0.000 claims 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 26
- 238000000034 method Methods 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 150000002367 halogens Chemical class 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 18
- -1 NRSO 2 Inorganic materials 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004429 atom Chemical group 0.000 claims 13
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 12
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 208000004296 neuralgia Diseases 0.000 claims 7
- 230000001154 acute effect Effects 0.000 claims 6
- 125000001118 alkylidene group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 208000006561 Cluster Headache Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000007914 Labor Pain Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000012696 congenital leptin deficiency Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000003963 dichloro group Chemical group Cl* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 201000011384 erythromelalgia Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 208000001022 morbid obesity Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 0 CN1CC(*)CCC1 Chemical compound CN1CC(*)CCC1 0.000 description 3
- UYDOZXVIMKMUBB-UHFFFAOYSA-N CC(C[U]C1)C1NC Chemical compound CC(C[U]C1)C1NC UYDOZXVIMKMUBB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Structural Engineering (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Materials Engineering (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51508803P | 2003-10-28 | 2003-10-28 | |
| US60/515,088 | 2003-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006118312A true RU2006118312A (ru) | 2007-12-10 |
Family
ID=34549374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006118312/04A RU2006118312A (ru) | 2003-10-28 | 2004-10-28 | Бензимидазолы, полезные в качестве модуляторов ионных каналов |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7309716B2 (https=) |
| EP (1) | EP1678145A2 (https=) |
| JP (1) | JP2007521325A (https=) |
| KR (1) | KR20060115396A (https=) |
| CN (1) | CN1902181A (https=) |
| AU (1) | AU2004285053B2 (https=) |
| CA (1) | CA2543918A1 (https=) |
| IL (1) | IL175252A0 (https=) |
| NO (1) | NO20062426L (https=) |
| NZ (1) | NZ547109A (https=) |
| RU (1) | RU2006118312A (https=) |
| WO (1) | WO2005042497A2 (https=) |
| ZA (1) | ZA200603864B (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2379294C1 (ru) * | 2008-05-19 | 2010-01-20 | Государственное образовательное учреждение высшего профессионального образования "Российский химико-технологический университет им. Д.И. Менделеева" (РХТУ им. Д.И. Менделеева) | [2-(азол-1-ил)алкилбензимидазол-1-ил]алкановые кислоты и их эфиры, способ их получения (варианты) и рострегуляторная композиция на их основе |
| RU2443690C1 (ru) * | 2010-12-13 | 2012-02-27 | Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации | 2-(9-антрилметил)амино-1-[3-(диметиламино)пропил]бензимидазол, обладающий свойствами флуоресцентного хемосенсора на катионы h+ |
| RU2480463C1 (ru) * | 2009-03-05 | 2013-04-27 | Дайити Санкио Компани, Лимитед | Пиридилокси производные, полезные в качестве активатора/модулятора гамма-рецептора, активируемого пролифератором пероксисом (ppar) гамма |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4564713B2 (ja) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法 |
| FR2880889B1 (fr) * | 2005-01-14 | 2007-04-06 | Merck Sante Soc Par Actions Si | Derives de l'acide 1h-indole-3-carboxylique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |
| GB0514018D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| BRPI0613229A2 (pt) * | 2005-07-12 | 2011-01-04 | Bayer Cropscience Sa | compostos, processo para a preparação de composto, composição fungicida e método para o combate curativo ou preventivo de fungo fitopatogênico |
| AR057455A1 (es) * | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| KR20080035700A (ko) * | 2005-08-15 | 2008-04-23 | 아이알엠 엘엘씨 | Ｔｐｏ 모방체로서의 화합물 및 조성물 |
| ES2691411T3 (es) | 2006-03-27 | 2018-11-27 | Wex Medical Limited | Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia |
| US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
| GEP20125702B (en) | 2007-06-29 | 2012-12-10 | Pfizer | Benzimidazole derivatives |
| AU2008310660A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| EA038941B1 (ru) | 2007-11-06 | 2021-11-12 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |
| EP2582666B1 (en) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
| CA2828456C (en) * | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
| CA2849057C (en) * | 2011-09-19 | 2021-05-11 | Vitas Pharma Research Pvt Ltd | Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections |
| EP2809656A2 (en) | 2011-12-28 | 2014-12-10 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
| US20130172342A1 (en) | 2011-12-28 | 2013-07-04 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| US20150203812A1 (en) * | 2014-01-20 | 2015-07-23 | Francesco Tombola | Inhibitors of Voltage Gated Ion Channels |
| US10913736B2 (en) * | 2014-08-22 | 2021-02-09 | University Of Washington | Specific inhibitors of methionyl-tRNA synthetase |
| CN104926745A (zh) * | 2015-07-14 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途 |
| CN104974103A (zh) * | 2015-07-14 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途 |
| BR112018002115A2 (pt) * | 2015-08-20 | 2018-09-18 | Boehringer Ingelheim Int | benzamidas aneladas |
| SI3348547T1 (sl) * | 2015-09-11 | 2020-10-30 | Sumitomo Dainippon Pharma Co., Ltd. | Derivati benzimidazola kot zaviralci NAV 1.7 (natrijevi kanalčki, napetostno odvisni, tip IX, podenota alfa (SCN9A)) za zdravljenje bolečine, disurije in multiple skleroze |
| GB201619694D0 (en) * | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| US11447471B2 (en) | 2017-06-23 | 2022-09-20 | Kyowa Kirin Co., Ltd. | α,β-unsaturated amide compound |
| KR101938982B1 (ko) | 2017-07-17 | 2019-01-15 | 연세대학교 산학협력단 | 자가포식 조절제를 포함하는 대사성 질환 치료용 약학 조성물 |
| KR102070882B1 (ko) * | 2017-10-17 | 2020-01-29 | 성균관대학교산학협력단 | Bietpc를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| CA3105657A1 (en) | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
| CN120097859A (zh) * | 2019-02-19 | 2025-06-06 | 加利福尼亚大学董事会 | Nurr1受体调节剂 |
| MA53521B1 (fr) * | 2021-05-12 | 2023-03-31 | Univ Ibn Tofail | Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications |
| US20240300939A1 (en) | 2021-06-14 | 2024-09-12 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| EP4408941A1 (en) * | 2021-09-30 | 2024-08-07 | Universidade Do Porto | Antifouling compound, method and uses thereof |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| US11478464B1 (en) | 2022-02-06 | 2022-10-25 | King Faisal University | Method for treating inflammation |
| US11786535B1 (en) | 2023-02-22 | 2023-10-17 | King Faisal University | Methods of inhibiting cyclooxygenase |
| WO2025067475A1 (zh) * | 2023-09-28 | 2025-04-03 | 四川大学华西医院 | 一类镇痛的化合物及其制备方法和用途 |
| WO2026015548A1 (en) * | 2024-07-08 | 2026-01-15 | Convelo Therapeutics, Inc. | Cyp51 inhibitors and method of using same |
| GB202412414D0 (en) * | 2024-08-23 | 2024-10-09 | Univ Bradford | Methods for treating cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL280954A (https=) * | 1961-07-14 | |||
| US4088768A (en) | 1975-05-06 | 1978-05-09 | Eli Lilly And Company | N-heterocyclic ureas as immune regulants |
| DK40192D0 (da) * | 1992-03-26 | 1992-03-26 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| AU4055300A (en) | 1999-04-02 | 2000-10-23 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of Bradykinin B2 receptors |
| IL146403A0 (en) * | 1999-06-22 | 2002-07-25 | Neurosearch As | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| US6316474B1 (en) * | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
| JP2004503527A (ja) * | 2000-06-13 | 2004-02-05 | イーライ・リリー・アンド・カンパニー | スルホンアミド誘導体 |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
-
2004
- 2004-10-28 AU AU2004285053A patent/AU2004285053B2/en not_active Ceased
- 2004-10-28 EP EP04796881A patent/EP1678145A2/en not_active Withdrawn
- 2004-10-28 JP JP2006538402A patent/JP2007521325A/ja active Pending
- 2004-10-28 KR KR1020067010407A patent/KR20060115396A/ko not_active Withdrawn
- 2004-10-28 ZA ZA200603864A patent/ZA200603864B/en unknown
- 2004-10-28 NZ NZ547109A patent/NZ547109A/en not_active IP Right Cessation
- 2004-10-28 WO PCT/US2004/036297 patent/WO2005042497A2/en not_active Ceased
- 2004-10-28 RU RU2006118312/04A patent/RU2006118312A/ru not_active Application Discontinuation
- 2004-10-28 CA CA002543918A patent/CA2543918A1/en not_active Abandoned
- 2004-10-28 US US10/977,609 patent/US7309716B2/en not_active Expired - Fee Related
- 2004-10-28 CN CNA2004800392479A patent/CN1902181A/zh active Pending
-
2006
- 2006-04-27 IL IL175252A patent/IL175252A0/en unknown
- 2006-05-29 NO NO20062426A patent/NO20062426L/no not_active Application Discontinuation
-
2007
- 2007-11-01 US US11/933,724 patent/US7705031B2/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2379294C1 (ru) * | 2008-05-19 | 2010-01-20 | Государственное образовательное учреждение высшего профессионального образования "Российский химико-технологический университет им. Д.И. Менделеева" (РХТУ им. Д.И. Менделеева) | [2-(азол-1-ил)алкилбензимидазол-1-ил]алкановые кислоты и их эфиры, способ их получения (варианты) и рострегуляторная композиция на их основе |
| RU2480463C1 (ru) * | 2009-03-05 | 2013-04-27 | Дайити Санкио Компани, Лимитед | Пиридилокси производные, полезные в качестве активатора/модулятора гамма-рецептора, активируемого пролифератором пероксисом (ppar) гамма |
| RU2443690C1 (ru) * | 2010-12-13 | 2012-02-27 | Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации | 2-(9-антрилметил)амино-1-[3-(диметиламино)пропил]бензимидазол, обладающий свойствами флуоресцентного хемосенсора на катионы h+ |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060115396A (ko) | 2006-11-08 |
| AU2004285053B2 (en) | 2010-10-21 |
| ZA200603864B (en) | 2007-09-26 |
| AU2004285053A1 (en) | 2005-05-12 |
| US7309716B2 (en) | 2007-12-18 |
| JP2007521325A (ja) | 2007-08-02 |
| NZ547109A (en) | 2010-03-26 |
| WO2005042497A3 (en) | 2005-07-21 |
| US20050209282A1 (en) | 2005-09-22 |
| EP1678145A2 (en) | 2006-07-12 |
| CN1902181A (zh) | 2007-01-24 |
| WO2005042497A2 (en) | 2005-05-12 |
| US20080306129A1 (en) | 2008-12-11 |
| US7705031B2 (en) | 2010-04-27 |
| CA2543918A1 (en) | 2005-05-12 |
| NO20062426L (no) | 2006-05-29 |
| IL175252A0 (en) | 2006-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006118312A (ru) | Бензимидазолы, полезные в качестве модуляторов ионных каналов | |
| CN103570738B (zh) | 新型青蒿素衍生物及其制法和应用 | |
| RU2358975C2 (ru) | Пирролопиримидиноновые производные | |
| EP0670832A1 (en) | Hepatobiliary magnetic resonance contrast agents | |
| ZA200406709B (en) | Pyrimidine derivatives | |
| RU2007111897A (ru) | Хиназолины, полезные в качестве модуляторов ионных каналов перекрестные ссылки на родственные заявки | |
| DE3207033C2 (de) | Amidinverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel | |
| AU650325B2 (en) | Novel nitrogenous macrocyclic ligands, their preparation method, polymetallic complexes, and a diagnostic and therapeutical composition | |
| RU2002132253A (ru) | Производные 2-ацилиндола, их применение (варианты) и способ получения, лекарственное средство и способ его получения, противоопухолевое средство и способ его получения | |
| WO1985001727A1 (en) | Novel synthetic methods for non-ionic radiographic contrast media | |
| AU2005233382C1 (en) | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | |
| TW201735B (https=) | ||
| EP4342900B1 (en) | Sesquiterpene derivatives as well as pharmaceutical compositions thereof, preparation method therefor, and use thereof | |
| CA2229664A1 (en) | Formyl derivatives as nonionic contrast media | |
| CN120019057A (zh) | 葫芦脲类化合物及其医药用途 | |
| ES2827795T3 (es) | Derivado de C-glucósido que contiene un anillo de fenilo fusionado o una sal farmacéuticamente aceptable del mismo, proceso para preparar el mismo y composición farmacéutica que comprende el mismo | |
| WO2005062913A2 (en) | Triplide 5,6-derivatives as immunomodulators and anticancer agents | |
| HUP0202706A2 (hu) | D4 antagonistákként alkalmazható benzizoxazolil-, piridoizoxazolil- és benzitienil-fenoxi-származékok, intermedierjeik, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| EP0642492B1 (en) | 5,5'-/(1,3-propanediyl) bis-/imino(2-oxo-2,1-ethanediyl)acetylimino/bis(2,4,6-triiodo-1,3-benzenedicarboxyamides), and contrast media containing them | |
| EP0699198B1 (en) | N-benzoylmethyl substituted paroxetine derivatives | |
| AU764788B2 (en) | Contrast media for angiography | |
| US8871983B2 (en) | Lipid compounds for suppression of tumorigenesis | |
| KR20080017028A (ko) | 바이페닐 및 나프틸―페닐 하이드록삼산 유도체 | |
| JP6814470B2 (ja) | モルヒナン誘導体 | |
| EA029372B1 (ru) | Пиразолопиримидиновые соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20071213 |